ASCO® 2024 Summary: "Treatment of Relapsed HL - Updated Options in L…

2024 ASCO® Annual Meeting Insights Hub

P. Johnson

Treatment Strategies for Hematocrit Control in PV

Insights from 2023 ASH Annual Meeting

A. Zhou

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Emerging and Current Treatment for Hodgkin Lymphoma in 2024

Indy Hematology Review

S. Ansell

State of the Art and Next Questions: Aggressive B-Cell Lymphomas

SOHO Highlights: State of the Art and Next Questions

G. Nowakowski

Lymphoma Hot Topics in 2024: Focus on DLBCL and cHL

Yale Cancer Center

T. Sethi

Treatment Updates and Management of Hodgkin Lymphoma

Integrity CE

A. Niu, D. Wallace, M. Cortese

Summary of Recent Updates in Advanced Hodgkin Lymphoma

SOHO Brazil 2024

C. Moskowitz

Safety Profile of Ruxolitinib in Patients With MF

Icahn School of Medicine at Mount Sinai

D. Tremblay

Standards of Care and Future Directions in FL

Martin Dreyling

Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…

Daniel Addison

CLL/SLL: Outcomes of Pts With Richter's Transformation Without Prior…

Insights from 2023 ASH Annual Meeting

A. Kittai

Summary of Recent Updates in R/R HL

SOHO Brazil 2024

C. Moskowitz

EHA 2024 Insights: Treatment of Advanced Stage, High-Risk Hodgkin's …

Insights from 2024 EHA Annual Meeting

M. Salamoon

NCCN Guidelines for the Treatment of cHL: A New Standard of Care

Stephen M. Ansell

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

ASH 2022 Conference Coverage

M. McMullin

Prevalence and Prediction of Ruxolitinib Treatment Emergent Thromboc…

Insights from 2023 ASH Annual Meeting

D. Tremblay

Diagnosis and Goals of Therapy in PV

Northwestern Medicine Oncology and Hematology

B. Stein

Overview of Hematopoietic Cell Transplantation

Fred Hutch 13th Annual Comprehensive Hematology & Oncology Review Course

R. Salit

Update on Cellular Therapy in Lymphoma

Total Health

B. Randolph